Vitamin D and axonal injury in multiple sclerosis

Multiple Sclerosis

Volumn 22, Issue 8, 2016, Pages 1027-1031

  Sandberg, L ^a   Bistrom M ^a   Salzer, J ^a   Vagberg M ^a   Svenningsson, A ^a   Sundstrom P ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

axonal injury; multiple sclerosis; neurofilament light; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALEMTUZUMAB; BETA INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MITOXANTRONE; NATALIZUMAB; RITUXIMAB; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN L; VITAMIN D; MEMBRANE PROTEIN; NEUROFILAMENT LIGHT CHAIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AXONAL INJURY; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROFILAMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; SCORING SYSTEM; SWEDEN; VITAMIN BLOOD LEVEL; ADOLESCENT; ANALOGS AND DERIVATIVES; AXON; BLOOD; BRAIN; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; PROTECTION; RISK FACTOR; YOUNG ADULT; BLOOD SAMPLING; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ADULT; AGED; AXONS; BIOMARKERS; BRAIN; DISABILITY EVALUATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; PROSPECTIVE STUDIES; PROTECTIVE FACTORS; RISK FACTORS; SPINAL PUNCTURE; VITAMIN D; YOUNG ADULT;

EID: 84978091937     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515606986     Document Type: Article

References (17)

1. Ascherio A, Munger KL, Lunemann JD,. The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012; 8: 602-612.
2. Salzer J, Biström M, Sundström P,. Vitamin D and multiple sclerosis: Where do we go from here? Expert Rev Neurother 2014; 14: 9-18.
3. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832-2838.
4. Salzer J, Hallmans G, Nystrom M, et al. Vitamin D as a protective factor in multiple sclerosis. Neurology 2012; 79: 2140-2145.
5. Ascherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014; 71: 306-314.
6. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62: 60-65.
7. Lucas RM, Ponsonby AL, Dear K, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011; 76: 540-548.
8. Kuhle J, Plattner K, Bestwick JP, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler 2013; 19: 1597-1603.
9. Norgren N, Sundström P, Svenningsson A, et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004; 63: 1586-1590.
10. Salzer J, Svenningsson A, Sundström P,. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010; 16: 287-292.
11. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83-89.
12. Axelsson M, Malmestrom C, Gunnarsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014; 20: 43-50.
13. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
14. Spelman T, Gray O, Trojano M, et al. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Ann Neurol 2014; 76: 880-890.
15. Hanwell HE, Banwell B,. Assessment of evidence for a protective role of vitamin D in multiple sclerosis. Biochim Biophys Acta 2011; 1812: 202-212.
16. Pierrot-Deseilligny C, Rivaud-Pechoux S, Clerson P, et al. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord 2012; 5: 187-198.
17. Achiron A, Givon U, Magalashvili D, et al. Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study. Mult Scler 2015; 21: 767-775.